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Divergent roles for antigenic drive 
in the aetiology of primary versus 
dasatinib-associated CD8+ TCR-Vβ+ 
expansions
Anna Lissina1, James E. McLaren2, Mette Ilander3, Emma I. Andersson  3, Catherine  
S. Lewis1, Mathew Clement  2, Andrew Herman1, Kristin Ladell2, Sian Llewellyn-Lacey2, 
Kelly L. Miners2, Emma Gostick2, J. Joseph Melenhorst4, A. John Barrett4, David A. Price2, 
Satu Mustjoki3 & Linda Wooldridge1
CD8+ T-cell expansions are the primary manifestation of T-cell large granular lymphocytic leukemia 
(T-LGLL), which is frequently accompanied by neutropenia and rheumatoid arthritis, and also occur as a 
secondary phenomenon in leukemia patients treated with dasatinib, notably in association with various 
drug-induced side-effects. However, the mechanisms that underlie the genesis and maintenance of 
expanded CD8+ T-cell receptor (TCR)-Vβ+ populations in these patient groups have yet to be fully 
defined. In this study, we performed a comprehensive phenotypic and clonotypic assessment of 
expanded (TCR-Vβ+) and residual (TCR-Vβ−) CD8+ T-cell populations in T-LGLL and dasatinib-treated 
chronic myelogenous leukemia (CML) patients. The dominant CD8+ TCR-Vβ+ expansions in T-LGLL 
patients were largely monoclonal and highly differentiated, whereas the dominant CD8+ TCR-Vβ+ 
expansions in dasatinib-treated CML patients were oligoclonal or polyclonal, and displayed a broad 
range of memory phenotypes. These contrasting features suggest divergent roles for antigenic drive in 
the immunopathogenesis of primary versus dasatinib-associated CD8+ TCR-Vβ+ expansions.
T-cell large granular lymphocytic leukemia (T-LGLL) is a chronic lymphoproliferative disorder characterized 
by the clonal expansion of mature CD3+ CD8+ cells1–5. Although the incidence of T-LGLL is relatively low, it 
nonetheless occurs more commonly than other proliferative aberrations within the CD8+ T-cell compartment, 
and there is no effective cure6. The disease typically afflicts individuals later in life (mean age of onset, ~60 years), 
but can also develop after allogeneic organ or stem cell transplantation4,7. Neutropenia complicates 70–80% of 
cases4,8,9. In addition, T-LGLL is strongly associated with autoimmune disorders, most commonly rheumatoid 
arthritis (RA), which affects ~30% of patients4,10. T-LGLL is currently managed with low-dose immunosuppres-
sive agents6, primarily to combat the clinical manifestations of neutropenia, but response rates remain subopti-
mal. A better understanding of the condition is therefore required to guide novel and more specific therapeutic 
interventions.
CD8+ T-cell expansions have also been reported in patients undergoing treatment with the promiscuous 
tyrosine kinase inhibitor dasatinib, which is licensed as a first line therapeutic option in the management of 
chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leu-
kemia (ALL)11–16. In some cases, these expanded CD8+ T-cells can even mimic T-cell large granular lymphocytes 
(T-LGLs). Dasatinib-associated CD8+ T-cell expansions have been linked with adverse side-effects, including 
pleural effusions and colitis14,15, and beneficial outcomes, including delayed progression and long-term remission 
in leukemia patients12,13,17.
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A number of studies have suggested that clonal CD8+ T-cell expansions in T-LGLL patients either arise in 
response to an unknown persistent antigen18,19 or occur via neoplastic transformation of genes involved in cel-
lular homeostasis or proliferation20–22. An alternative view is that such expansions originate within a primary 
antigen-specific response and then acquire genetic mutations that confer additional proliferative and/or survival 
advantages1. Particular attention has been devoted in this regard to the Janus kinase (JAK)/signal transducer and 
activator of transcription (STAT) pathway23. Indeed, a large proportion of T-LGLL patients have been found to 
harbor somatic gain-of-function mutations in genes encoding the STAT family of proteins24. The majority of these 
mutations affect STAT325–27, with others localizing most commonly to STAT5B28.
To inform these distinct mechanistic hypotheses, we performed an in-depth comparison of CD8+ T-cell 
expansions in T-LGLL and dasatinib-treated CML patients. A molecular approach was used to identify T-cell 
receptor (TCR) clonotypes within the expanded TCR-Vβ-defined CD8+ T-cell populations, and flow cytometry 
was used to assess multiple phenotypic markers with reference to non-expanded (TCR-Vβ−) and cytomegalovirus 
(CMV)-specific CD8+ T-cells. The data reveal striking phenotypic and clonotypic differences that suggest diver-
gent roles for antigenic drive in the aetiology of primary versus dasatinib-associated CD8+ TCR-Vβ+ expansions.
Results
Striking differences in the size and differentiation status of dominant CD8+ TCR-Vβ+ expan-
sions in T-LGLL and dasatinib-treated CML patients. Peripheral blood mononuclear cell (PBMC) 
samples from T-LGLL and dasatinib-treated CML patients (Table 1) were characterized by flow cytometry 
(Fig. 1A,B). Dominant TCR-Vβ+ expansions were identified using a panel of monoclonal antibodies (mAbs) 
covering 75% of the TRBV gene-encoded repertoire, and phenotypically distinct subsets of CD8+ T-cells were 
classified as follows: naïve (N, CCR7+ CD45-RA+); central-memory (CM, CCR7+ CD45-RA−); effector-memory 
(EM, CCR7− CD45-RA−); and effector (E, CCR7− CD45-RA+). The dominant TCR-Vβ+ expansions in T-LGLL 
patients were significantly larger than the dominant TCR-Vβ+ expansions in dasatinib-treated CML patients 
(Fig. 1B,C, Supplementary Figure 1, Table 1). Moreover, the dominant TCR-Vβ+ expansions in T-LGLL patients 
were almost exclusively populated with terminally differentiated (CCR7− CD45-RA+) effector CD8+ T-cells, 
whereas the dominant TCR-Vβ+ expansions in dasatinib-treated CML patients were more broadly constituted 
across the phenotypic spectrum of CD8+ T-cells (Fig. 2A).
Side-by-side comparisons of the expanded (TCR-Vβ+) and residual (TCR-Vβ−) CD8+ T-cell populations 
revealed an inverted EM/E profile in T-LGLL patients. Terminally differentiated effector cells predominated in 
Patient 
ID
Leukemia 
type
Additional clinical  
complications
Age at 
diagnosis 
(years)
Age at 
sample 
collection 
(years)
Duration of 
dasatinib treatment 
at sample collection 
(years, months) Sex
Dominant TCR-Vβ 
expansion (Arden 
nomenclature)
Size of TCR-Vβ 
expansion (% of CD8+ 
T-cell population)
Presence of 
STAT3 or STAT5B 
mutations
1 T-LGLL
Neutropenia, thrombocytopenia, 
leukopenia, B-cell dyscrasia, 
hypergammaglobulinemia
58 64 N/A F 1 51.1 STAT3
2 T-LGLL B-cell dyscrasia, unspecified collagenosis 72 73 N/A F 22 81.9 STAT5B
3 T-LGLL Anemia, neutropenia, seronegative RA 74 74 N/A M 16 66.1 STAT3
4 T-LGLL Anemia, neutropenia, thrombocytopenia 66 67 N/A M 5.1 72 No
5 T-LGLL None 59 59 N/A M 3 94.3 No
6 T-LGLL None 50 50 N/A F 17 82.8 STAT5B
7 T-LGLL Neutropenia, anemia 27 38 N/A M 20 73.4 STAT3
8 T-LGLL Neutropenia 24 37 N/A F 14 70.5 STAT3
9 T-LGLL Neutropenia 50 56 N/A F 13.6 84 STAT3
10 T-LGLL Anemia, thrombocytopenia 85 87 N/A M 8 62.5 No
11 T-LGLL Anemia 65 67 N/A M 2 57 No
12 CML None 71 72 1, 7 F 13.2 43.4 No
13 CML None 44 44 0, 6 F 14 7.25 No
14 CML None 60 62 1, 2 F 3 9.67 No
15 CML Ulcerative colitis 47 47 0, 6 M 3 10.7 No
16 CML None 28 45 4, 7 M 5.3 5.61 No
17 CML None 45 46 1, 2 M 7.2 31 No
18 CML Pleural effusion 58 59 0, 8 M
2 8.8
No
8 9.99
19 CML None 67 70 2, 4 M
22 11.9
No
23 13.1
20 CML None 45 46 0, 9 F 2 12.4 No
21 CML None 58 65 1, 1 F 14 15.5 No
Table 1. Clinical details of T-LGLL and dasatinib-treated CML patients.
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the TCR-Vβ+ fraction (mean, ~90%), but were significantly less common in the TCR-Vβ− fraction (mean, ~40%), 
which incorporated higher frequencies of naïve and less differentiated memory cells (Fig. 2B, left panel). In con-
trast, the expanded (TCR-Vβ+) and residual (TCR-Vβ−) CD8+ T-cell populations were phenotypically alike in 
dasatinib-treated CML patients, with a relatively balanced EM/E profile reflecting mean frequencies of ~40% for 
each subset in the TCR-Vβ+ fraction (Fig. 2B, right panel). Accordingly, the dominant CD8+ TCR-Vβ+ expan-
sions in T-LGLL patients were significantly more differentiated than the dominant CD8+ TCR-Vβ+ expansions 
in dasatinib-treated CML patients (Fig. 2C, left panel).
The residual (TCR-Vβ−) CD8+ T-cell populations were phenotypically similar in T-LGLL and 
dasatinib-treated CML patients, mirroring the subset distribution normally observed in healthy donor PBMCs 
(Fig. 2C, right panel). However, relatively low frequencies of naïve and central-memory cells were present in 
both groups, potentially reflecting advanced age in the T-LGLL cohort (mean, 61 years) and preferential expan-
sion of effector-memory cells in dasatinib-treated CML patients. Of note, considerable variability was detected 
among patients with respect to the frequency of each subset in the TCR-Vβ− fraction, and a comparably broad 
inter-individual spread was observed among dasatinib-treated CML patients in the TCR-Vβ+ fraction (SD: N, 
17.2; CM, 4; EM, 23.6; E, 24.4). In contrast, subset distribution was tightly clustered among T-LGLL patients in 
the TCR-Vβ+ fraction (SD: N, 2.7; CM, 0.07; EM, 8.9; E, 9.2).
Dominant CD8+ TCR-Vβ+ expansions in T-LGLL and dasatinib-treated CML patients are phe-
notypically distinct. In T-LGLL patients, the dominant CD8+ TCR-Vβ+ expansions displayed a classical 
antigen-driven phenotype, reflected by significantly higher expression levels of CD57 and 2B4 and significantly 
lower expression levels of CD27 and CD127 compared with the residual CD8+ TCR-Vβ− populations (Fig. 3A, 
top panel). The dominant CD8+ TCR-Vβ+ expansions in these patients were also characterized by a lack of 
CTLA-4, CD160, and Tim-3 (data not shown), and relatively low expression levels of PD-1 and BTLA (Fig. 3A, 
top panel). In contrast, there were no significant phenotypic differences between the expanded (TCR-Vβ+) and 
residual (TCR-Vβ−) CD8+ T-cell populations in dasatinib-treated CML patients (Fig. 3A, bottom panel).
Inter-group comparisons revealed that the dominant CD8+ TCR-Vβ+ expansions in T-LGLL patients 
expressed significantly higher levels of CD57 and 2B4 and significantly lower levels of CD27 and CD127 com-
pared with the dominant CD8+ TCR-Vβ+ expansions in dasatinib-treated CML patients (Fig. 3B, top panel). 
Figure 1. Quantification of dominant CD8+ TCR-Vβ+ expansions in T-LGLL and dasatinib-treated CML 
patients. (A) Gating strategy for the identification of viable CD14− CD19− CD3+ CD8+ cells within PBMCs. 
(B) Representative flow cytometry plots showing expanded (TCR-Vβ+) and residual (TCR-Vβ−) CD8+ T-cell 
populations in T-LGLL and dasatinib-treated CML patients. (C) Percent frequencies of dominant CD8+ 
TCR-Vβ+ expansions in T-LGLL (n = 11) and dasatinib-treated CML patients (n = 10). Statistical comparisons 
were performed using the Mann-Whitney U test. ***P < 0.0001. Error bars represent SD.
www.nature.com/scientificreports/
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Figure 2. Differentiation status of expanded (TCR-Vβ+) and residual (TCR-Vβ−) CD8+ T-cells in T-LGLL 
and dasatinib-treated CML patients. (A) Representative flow cytometry plots showing CCR7 and CD45-RA 
expression among TCR-Vβ+ (black dots) and TCR-Vβ− CD8+ T-cells (grey density clouds) in T-LGLL (left 
panel) and dasatinib-treated CML patients (right panel). (B) Percent frequencies of TCR-Vβ+ (black dots) 
and TCR-Vβ− CD8+ T-cells (white dots) displaying the indicated differentiation phenotypes in T-LGLL (left 
panel) and dasatinib-treated CML patients (right panel). (C) Percent frequencies of TCR-Vβ+ (left panel) and 
TCR-Vβ− CD8+ T-cells (right panel) displaying the indicated differentiation phenotypes in T-LGLL (black 
dots) and dasatinib-treated CML patients (white dots). Statistical comparisons were performed using the 
Mann-Whitney U test. ***P < 0.0001, *P < 0.01. Horizontal bars indicate mean values. N, naïve; CM, central-
memory; EM, effector-memory; E, effector.
www.nature.com/scientificreports/
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However, no significant phenotypic differences were observed between the residual CD8+ TCR-Vβ− populations 
in T-LGLL patients and the residual CD8+ TCR-Vβ− populations in dasatinib-treated CML patients (Fig. 3B, 
bottom panel).
Figure 3. Phenotypic analysis of expanded (TCR-Vβ+) and residual (TCR-Vβ−) CD8+ T-cells in T-LGLL and 
dasatinib-treated CML patients. (A) Percent frequencies of TCR-Vβ+ (black dots) and TCR-Vβ− CD8+ T-cells 
(white dots) expressing the indicated markers in T-LGLL (top panel) and dasatinib-treated CML patients 
(bottom panel). (B) Percent frequencies of TCR-Vβ+ (top panel) and TCR-Vβ− CD8+ T-cells (bottom panel) 
expressing the indicated markers in T-LGLL (black dots) and dasatinib-treated CML patients (white dots). 
Statistical comparisons were performed using the Mann-Whitney U test. ***P < 0.0001, **P < 0.001, *P < 0.01. 
Horizontal bars indicate mean values.
www.nature.com/scientificreports/
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Phenotypic parallels between CMV-specific CD8+ T-cells and dominant CD8+ TCR-Vβ+ 
expansions in T-LGLL patients. In further experiments, we evaluated the phenotypic characteris-
tics of CMV pp65-specific CD8+ T-cells in healthy HLA-A2+ individuals (Fig. 4). Terminally differentiated 
(CCR7− CD45-RA+) effector cells predominated in the NLV/HLA-A*0201 tetramer+ fraction (Fig. 4A), 
which also expressed low levels of CD27, intermediate levels of CD127, and high levels of CD57 (Fig. 4B). This 
effector-polarized differentiation profile closely resembles the phenotype of dominant CD8+ TCR-Vβ+ expan-
sions in T-LGLL patients. In contrast, the NLV/HLA-A*0201 tetramer– fraction incorporated higher frequencies 
of naïve and less differentiated memory cells, with a balanced EM/E profile reminiscent of the dominant CD8+ 
TCR-Vβ+ expansions in dasatinib-treated CML patients and the residual CD8+ TCR-Vβ− populations in both 
T-LGLL and dasatinib-treated CML patients.
Dominant CD8+ TCR-Vβ+ expansions in T-LGLL and dasatinib-treated CML patients are clo-
notypically distinct. Next, we performed a molecular analysis of expressed TRB gene rearrangements 
in CD3+ CD8+ TCR-Vβ+ cell populations sorted directly ex vivo from T-LGLL and dasatinib-treated CML 
patients. The dominant CD8+ TCR-Vβ+ expansions in T-LGLL patients were largely monoclonal (Fig. 5A), 
whereas the dominant CD8+ TCR-Vβ+ expansions in dasatinib-treated CML patients were either oligoclonal 
or polyclonal (Fig. 5B). However, in vitro culture revealed the presence of additional clonotypes with identi-
cal TRBV gene-encoded segments in the dominant CD8+ TCR-Vβ+ expansions isolated from T-LGLL patients 
(Supplementary Figure 2). Although clonotypic drift is a recognized feature of dominant T-LGL populations in 
vivo2, the emergence of subdominant clonotypes in vitro likely reflects a proliferative advantage over more termi-
nally differentiated and potentially senescent dominant clonotypes.
Dasatinib administration rapidly increases lymphocyte numbers and further inflates dominant 
CD8+ TCR-Vβ+ expansions. To examine the impact of dasatinib on the CD8+ T-cell repertoire in CML 
patients, we administered 100 mg of the drug and compared blood samples drawn at baseline with blood samples 
drawn after 1 hour. The percent frequencies of the dominant CD8+ TCR-Vβ+ expansions increased significantly 
over this brief time period (Fig. 6A). However, the corresponding total lymphocyte counts also increased sig-
nificantly (Fig. 6B), indicating that the effects of dasatinib were not confined to the dominant CD8+ TCR-Vβ+ 
expansions29.
Discussion
In this study, we performed a comprehensive phenotypic and clonotypic assessment of expanded (TCR-Vβ+) 
and residual (TCR-Vβ−) CD8+ T-cell populations in T-LGLL and dasatinib-treated CML patients. The dominant 
CD8+ TCR-Vβ+ expansions in T-LGLL patients were significantly larger and more differentiated than the dom-
inant CD8+ TCR-Vβ+ expansions in dasatinib-treated CML patients. Molecular analysis of expressed TRB gene 
rearrangements further showed that the dominant CD8+ TCR-Vβ+ expansions in T-LGLL patients were largely 
monoclonal, whereas the dominant CD8+ TCR-Vβ+ expansions in dasatinib-treated CML patients were either 
oligoclonal or polyclonal. These distinct features suggest that key mechanistic differences underlie the genesis and 
maintenance of dominant CD8+ TCR-Vβ+ expansions in T-LGLL and dasatinib-treated CML patients.
In conjunction with a terminally differentiated (CCR7− CD45-RA+) effector phenotype, the dominant 
CD8+ TCR-Vβ+ expansions in T-LGLL patients expressed high levels of CD57, which is thought to indicate 
replicative senescence as a consequence of antigen-driven proliferation30, and correspondingly low levels of 
Figure 4. Phenotypic analysis of CMV-specific CD8+ T-cells in healthy donors. (A) Percent frequencies 
of NLV/HLA-A*0201 tetramer+ (black dots) and NLV/HLA-A*0201 tetramer− CD8+ T-cells (white dots) 
displaying the indicated differentiation phenotypes in healthy donors (n = 6). (B) Percent frequencies of NLV/
HLA-A*0201 tetramer+ (black dots) and NLV/HLA-A*0201 tetramer− CD8+ T-cells (white dots) expressing 
the indicated markers in healthy donors (n = 6). Statistical comparisons were performed using the Mann-
Whitney U test. **P < 0.001, *P < 0.01. Horizontal bars indicate mean values. N, naïve; CM, central-memory; 
EM, effector-memory; E, effector.
www.nature.com/scientificreports/
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immunoregulatory markers, such as PD-131. These findings suggest a central role for persistent antigens in the 
pathogenesis of T-LGLL. In line with this interpretation, we found strong phenotypic parallels between CMV 
pp65-specific CD8+ T-cells in healthy donors and the dominant CD8+ TCR-Vβ+ expansions in T-LGLL patients. 
Figure 5. Clonotypic analysis of dominant CD8+ TCR-Vβ+ expansions in T-LGLL and dasatinib-treated CML 
patients. (A) Percent frequencies of expanded (TCR-Vβ+) CD8+ T-cell clonotypes in T-LGLL patients. (B) 
Percent frequencies of expanded (TCR-Vβ+) CD8+ T-cell clonotypes in dasatinib-treated CML patients. Gene 
usage and CDR3β amino acid sequences are listed, and dominant clonotypes are highlighted in color. Data are 
shown for two co-dominant CD8+ TCR-Vβ+ expansions in dasatinib-treated CML patient 19.
www.nature.com/scientificreports/
8SCIENTIFIC REPORTS |  (2018) 8:2534  | DOI:10.1038/s41598-017-18062-x
Moreover, clonal CD8+ CD57+ cells in T-LGLL patients can be derived from CD8+ CD57– progenitors in vitro, 
suggesting that an earlier memory compartment sustains the dominant CD8+ TCR-Vβ+ expansions in vivo18.
STAT3 is a latent transcription factor and a key component of the JAK/STAT signalling pathway32, linked in a 
dysregulated state with tumor growth and pro-oncogenic inflammation33. Indeed, persistent activation of STAT3 
has been observed in at least 22 different cancers34, including T-LGLL21,35. Genomic studies have revealed that up 
to 40% of T-LGLL patients harbour STAT mutations26. Although the majority of these somatic variants localize 
to STAT326, comparable mutations have been observed in STAT5B28. Other signalling pathways can also impact 
the function of STAT321,36. On the basis of these observations, it has been proposed that STAT mutations drive the 
monoclonal CD8+ TCR-Vβ+ expansions that characterize T-LGLL. However, primary T-LGLs are by no means 
immortal in vitro like many classical tumor cell lines37,38. It therefore seems more likely that STAT mutations accu-
mulate as a consequence of prolonged antigenic stimulation within a homeostatically conducive environment39,40.
In dasatinib-treated CML patients, the expanded (TCR-Vβ+) and residual (TCR-Vβ−) CD8+ T-cell popula-
tions were phenotypically similar and resembled healthy memory CD8+ T-cells. Moreover, the dominant CD8+ 
TCR-Vβ+ expansions were either oligoclonal or polyclonal, which may reflect either multiple antigen specificities 
or germline-encoded bias within a single antigen specificity41. Although the actions of dasatinib are poorly under-
stood, it is possible that the short half-life of the drug in vivo leads to diurnal cycles of systemic immunosuppres-
sion11,42. It has also been shown that naïve T-cells are more susceptible to the effects of dasatinib than memory 
T-cells43. Dasatinib therapy may therefore create an immunosuppressive environment that favors the expansion of 
pre-existing memory CD8+ T-cells, potentially mimicking the conditions encountered after allogeneic stem cell 
transplantation7 or during primary infection with certain persistent viruses44,45. This mechanistic interpretation 
is consistent with the absence of STAT mutations in dasatinib-associated CD8+ TCR-Vβ+ expansions (Table 1).
Collectively, our data support the view that monoclonal CD8+ TCR-Vβ+ expansions in T-LGLL patients 
arise in response to chronic antigen-driven stimulation and then acquire somatic mutations that provide further 
survival advantages (Fig. 7A). In contrast, the dominant CD8+ TCR-Vβ+ expansions in dasatinib-treated CML 
patients appear to be more benign and most likely originate from generic perturbations that affect the pre-existing 
pool of memory CD8+ T-cells (Fig. 7B). Further studies are therefore required to identify the antigenic culprits 
that trigger T-LGLL and characterize the dominant CD8+ TCR-Vβ+ expansions that potentially cause autoim-
mune side-effects and/or beneficially target leukemic cells in dasatinib-treated CML patients46.
Materials and Methods
Study subjects and samples. PBMCs used for the characterization of chronic viral antigen-specific CD8+ 
T-cell populations were isolated from the blood of healthy HLA-A2+ CMV+ individuals (age range, 24–72 years) 
via standard lymphocyte purification protocols. Equivalent samples from T-LGLL and dasatinib-treated CML 
patients were obtained with approval from the relevant local Ethics Committees and Institutional Review Boards. 
All subjects provided written informed consent in accordance with the Declaration of Helsinki. PBMCs from 
patients 7–11 were collected under protocols approved by the Institutional Review Board of the National Heart, 
Lung, and Blood Institute, National Institutes of Health, Bethesda MD, USA. All other patient samples were 
obtained from Helsinki University Hospital under protocols approved by The Hospital District of Helsinki and 
Uusimaa Medicinal Ethical Committee, Finland. Clinical details are summarized in Table 1 and Supplementary 
Table 1. The diagnosis of T-LGLL was based on the following WHO criteria: a monoclonal TCR rearrangement, 
the presence of an abnormal cytotoxic T-cell population with expression of CD3, CD8, and CD57 detected by 
flow cytometry, and a peripheral blood smear LGL count of >2 × 109/L. If all other criteria were met, a diagnosis 
of T-LGLL was also considered with a peripheral blood smear LGL count of <2 × 109/L. Screening for STAT3 and 
STAT5B mutations was performed via amplicon sequencing across the hotspot area47.
Figure 6. Influence of dasatinib on lymphocyte numbers and dominant CD8+ TCR-Vβ+ expansions in CML 
patients. (A) Percent frequencies of dominant CD8+ TCR-Vβ+ expansions in CML patients before and 1 hour 
after a single 100 mg dose of dasatinib. (B) Total lymphocyte counts in CML patients before and 1 hour after a 
single 100 mg dose of dasatinib. Statistical comparisons were performed using the Wilcoxon matched pairs test. 
Horizontal bars indicate mean values.
www.nature.com/scientificreports/
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Figure 7. Immunopathogenesis of dominant CD8+ TCR-Vβ+ expansions in T-LGLL and dasatinib-treated 
CML patients. (A) Hypothetical model showing the potential mechanisms that drive CD8+ TCR-Vβ+ 
expansions in T-LGLL patients. In this model, persistent antigenic drive and homeostatic cytokines facilitate 
the expansion of highly responsive clonotypes, which subsequently acquire somatic mutations that confer 
additional proliferative and/or survival advantages. These selection events culminate in the outgrowth of a 
dominant CD8+ TCR-Vβ+ population. Autoimmunity may be triggered via the release of pro-inflammatory 
mediators and/or self-antigen recognition via the expressed TCR. (B) Hypothetical model showing the potential 
mechanisms that drive CD8+ TCR-Vβ+ expansions in dasatinib-treated CML patients. In this model, the short 
half-life of dasatinib in vivo leads to diurnal cycles of systemic immunosuppression, which may provide a 
replicative niche for memory T-cells and/or promote the reactivation of persistent viruses, such as CMV. These 
effects drive polyclonal CD8+ TCR-Vβ+ expansions. Improved disease outcomes may arise as a consequence of 
CML-associated antigen cross-recognition via the expressed TCRs. EM, effector-memory; E, effector.
www.nature.com/scientificreports/
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Flow cytometry reagents. PE-conjugated HLA-A2 tetramers refolded around the CMV pp65495-503 
epitope NLVPMVATV (NLV) were generated as described previously48,49 and used at a final concentration 
of 10 μg/mL. Directly conjugated mAbs were obtained from commercial suppliers: (i) anti-CD3-APC-H7, 
anti-CD8-BV786, anti-CD14-BV510, anti-CD19-BV510, anti-CD45-RA-PerCP-Cy5.5, anti-CD57-APC, 
anti-CD127-BV421, anti-CD160-PerCP-Cy5.5, anti-CCR7-PE-Cy7, anti-CTLA-4-PE-Cy7, anti-BTLA-APC, 
anti-2B4-FITC, anti-2B4-PE, and anti-Tim-3-AF700 (BD Biosciences); (ii) anti-CD27-BV605 and anti-PD-1-PE/
Dazzle 594 (BioLegend); and (iii) a panel of anti-TCR-Vβ-FITC and anti-TCR-Vβ-PE mAbs (Beckman Coulter). 
The acute effects of dasatinib administration were monitored using an IOTest Beta Mark TCR Repertoire Kit 
(BD Biosciences). Non-viable cells were excluded from the analysis using LIVE/DEAD Fixable Aqua (Life 
Technologies). Data were acquired using a Fortessa X-20 flow cytometer (BD Biosciences) and analyzed with 
FlowJo software version 10.0.7 (Tree Star). Viable CD3+ CD8+ TCR-Vβ+ cells were sorted using an InfluxTM Cell 
Sorter (BD Biosciences).
Clonotypic analysis. Molecular analysis of expressed TRB gene rearrangements in flow-sorted CD3+ CD8+ 
TCR-Vβ+ cell populations was performed using a template-switch anchored RT-PCR50. Gene usage was assigned 
via web-based alignment of molecular transcripts in accordance with the ImMunoGeneTics (IMGT) information 
system (http://www.imgt.org).
Cell culture. Flow-sorted CD3+ CD8+ TCR-Vβ+ cells were stimulated non-specifically with 1 μg/mL phy-
tohemagglutinin (Fisher Scientific) in the presence of irradiated PBMCs from three healthy donors. Cultures 
were maintained in RPMI 1640 medium containing 100 U/mL penicillin, 100 mg/mL streptomycin, 2 mM 
L-glutamine, 10% heat-inactivated fetal bovine serum, and 5% heat-inactivated human AB serum (all from Life 
Technologies), supplemented with 200 IU/mL interleukin (IL)-2 and 25 ng/mL IL-15 (PeproTech).
Statistical analysis. Univariate statistical analyses were implemented using Prism 5 software (GraphPad). 
Comparisons between groups were performed using either the Mann-Whitney U test or the Wilcoxon matched 
pairs test. P values < 0.05 were considered significant.
Data availability. The data that support the findings of this study are available from the corresponding 
author on reasonable request.
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